Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544960 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00544960 is a Phase 2 study that has completed, run by Ascenta Therapeutics. The registered enrollment target is 106 participants.
The verdict
NCT00544960, a Phase 2 study, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer
Interventions
- DRUG AT-101 and docetaxel
- DRUG placebo and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00544960
The ClinicalTrials.gov registry entry for NCT00544960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AT-101 and docetaxel is the first listed.
NCT00544960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00544960 about?
NCT00544960 is a clinical study titled "A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer". This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer
What is the current status of trial NCT00544960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2007-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00544960?
The interventions under investigation include: AT-101 and docetaxel (DRUG), placebo and docetaxel (DRUG).
Who is sponsoring clinical trial NCT00544960?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.